INTRODUCTION AND HYPOTHESIS: To evaluate the efficacy and safety of the minimally invasive Ajust™ system in the treatment of stress urinary incontinence. METHODS: This was a prospective multicentre study. All patients with primary urodynamic stress urinary incontinence were prospectively selected to receive the Ajust™ procedure. The International Consultation on Incontinence-Short Form (ICI-SF), Women Irritative Prostate Symptoms Score (W-IPSS), PGI-S, and PGI-I questionnaires were used to evaluate the impact of incontinence and voiding dysfunction on QoL and to measure patient's perception of incontinence severity and improvement. RESULTS: From January 2009 to October 2009, 111 consecutive subjects were enrolled in the study. At 6 months, 102 were available for outcomes analysis. The subjective and objective cure rates were 85.7% and 91.4%, respectively. The ICI-SF and W-IPSS questionnaires showed a statistical significant improvement in symptom scores. CONCLUSIONS: In the short-term follow-up, the Ajust™ system was effective in restoring continence in more than 85% of subjects with a highly significant improvement in QoL.
INTRODUCTION AND HYPOTHESIS: To evaluate the efficacy and safety of the minimally invasive Ajust™ system in the treatment of stress urinary incontinence. METHODS: This was a prospective multicentre study. All patients with primary urodynamic stress urinary incontinence were prospectively selected to receive the Ajust™ procedure. The International Consultation on Incontinence-Short Form (ICI-SF), Women Irritative Prostate Symptoms Score (W-IPSS), PGI-S, and PGI-I questionnaires were used to evaluate the impact of incontinence and voiding dysfunction on QoL and to measure patient's perception of incontinence severity and improvement. RESULTS: From January 2009 to October 2009, 111 consecutive subjects were enrolled in the study. At 6 months, 102 were available for outcomes analysis. The subjective and objective cure rates were 85.7% and 91.4%, respectively. The ICI-SF and W-IPSS questionnaires showed a statistical significant improvement in symptom scores. CONCLUSIONS: In the short-term follow-up, the Ajust™ system was effective in restoring continence in more than 85% of subjects with a highly significant improvement in QoL.
Authors: Yik N Lim; Peter Dwyer; Reinhold Muller; Anna Rosamilia; Joseph Lee; Kobi Stav Journal: Int Urogynecol J Date: 2010-05-04 Impact factor: 2.894
Authors: Steven E Schraffordt Koops; Tanya M Bisseling; H Jorien van Brummen; A Peter M Heintz; Harry A M Vervest Journal: Am J Obstet Gynecol Date: 2006-01 Impact factor: 8.661
Authors: Bernard T Haylen; Dirk de Ridder; Robert M Freeman; Steven E Swift; Bary Berghmans; Joseph Lee; Ash Monga; Eckhard Petri; Diaa E Rizk; Peter K Sand; Gabriel N Schaer Journal: Int Urogynecol J Date: 2009-11-25 Impact factor: 2.894
Authors: Jordi Sabadell; Marta Palau-Gené; Eva Huguet; Anabel Montero-Armengol; Sabina Salicrú; Jose L Poza Journal: Int Urogynecol J Date: 2016-12-05 Impact factor: 2.894
Authors: Gert Naumann; Thomas Hagemeier; Stefan Zachmann; Aktham Al-Ani; Stefan Albrich; Christine Skala; Rosa Laterza; Misti Linaberry; Heinz Koelbl Journal: Int Urogynecol J Date: 2012-06-16 Impact factor: 2.894